Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 8, Number 8—August 2002


Outbreak of Serogroup W135 Meningococcal Disease after the Hajj Pilgrimage, Europe, 2000

Jean-François Aguilera*Comments to Author , Anne Perrocheau†, Christine Meffre‡, Susan Hahné§, and the W135 Working Group1
Author affiliations: *Communicable Disease Surveillance Centre, London, United Kingdom; †Institut de Veille Sanitaire, St. Maurice, France; ‡Rijksinstituut voor Volksgezondheid en Milieu (RIVM), European Programme for Intervention Epidemiology Training, Bilthoven, the Netherlands; §Communicable Disease Surveillance Centre, Cardiff, Wales, United Kingdom

Main Article

Table 3

Number (and ratio) of cases in United Kingdom (UK) and France before and after a French Ministry of Health recommendationa

UK (n=42)
France (n=24)
Measure of impact (Ratio France / ratio UK)
No. of cases
No. of cases
Before After After/
before Before After After/
Pilgrim cases (a) 8 0 3 1
Household contacts (b) 9 5 4 4
(a)+(b) 17 5 0.3 7 5 0.7 2.4 [0.5; 11.1]; p=0.27
Outside-of-household contacts (c) 2 4 2 5
No identified contact (d) 0 14 0 5
(c)+(d) 2 18 9 2 10 5 0.6 [0.1; 4.6]; p=0.62
All cases 19 23 1.2 9 15 1.7 1.4 [0.5; 3.8];p=0.61

aApril 8, 2000. Ratio is divided by the same ratio in the United Kingdom and its 95% confidence interval.

Main Article

1F. Carion and O. Ronveaux, Institut de Santé Publique, Brussels, Belgium; P. Nuorti, H. Kayhty, and N. Nguyen Tran Minh, Kansanterveyslaitos Folkhälsoinstitutet, National Public Health Institute, Helsinki, Finland; T. Breuer, U. Menzel, and V. Bremer, Robert Koch Institute, Berlin, Germany; J. Kool, Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, the Netherlands; L. Spanjaard, Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, the Netherlands; M. Arneborn and H. Götz, Smittskyddinstitutet, Stockholm, Sweden; P.Olcen, National Meningitidis Reference Laboratory, Örebro, Sweden; M. Ramsay, N. Noah, and E. Kaczmarski, Public Health Laboratory Service (PHLS), London, United Kingdom; J. Stuart, PHLS, Gloucester, United Kingdom; D. Levy-Bruhl, M.D. Matsika-Claquin, and J.C. Desenclos, Institut National de Veille Sanitaire, St-Maurice, France; M.K. Taha, Institut Pasteur, Paris, France; B. Iversen and D. Caugant, Folkehelsa, Oslo, Norway.